A comparison between the two PSMA-targeted radiopharmaceuticals ([18F]DCFPyL and [68Ga]Ga-PSMA-11) in the detection of BCR demonstrated that a [18F]DCFPyL PET scan following a [68Ga]Ga-PSMA-11 PET scan identified at least nine more additional lesions, due to a higher tumor-to-background contrast [88]. Here, FOLH1 is linked to neoplasm.